Millennium commences MLN8237 phase 3 trial in relapsed or refractory PTCL

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating MLN8237 in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), an aggressive form of lymphoma. The multi-center study with MLN8237, an investigational, oral, selective inhibitor of Aurora A kinase, will be conducted in Europe, North America, Latin America and the Asia-Pacific region.

"There is a significant unmet medical need for patients suffering from PTCL. As a leader in the development of novel therapies Millennium continues to work toward filling that need," said Karen Ferrante, M.D., Chief Medical Officer, Millennium. "MLN8237 is being explored across a broad range of hematological malignancies and solid tumors. The initiation of this trial represents another major achievement in advancing the Millennium pipeline."